Akebia Therapeutics, Inc. (AKBA) Market Cap & Valuation Ratios
Akebia Therapeutics, Inc. (AKBA) has a market cap of $157.1M and a price-to-sales ratio of 0.7, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AKBAAkebia Therapeutics, Inc.Follow AKBA — free
—
Price chart with a free account
- Market cap
- 157.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| AKBA | 0.2 | — | 0.2 | — | — | +8% | -7% | — |
| AQST | 0.5 | — | 8.4 | — | -9.2% | +23% | -98% | — |
| EOLS | 0.5 | — | 1.8 | — | -4.7% | +14% | -6% | -26% |
| TLRY | 0.4 | — | 0.4 | — | — | +16% | -9% | -6% |
| EBS | 0.3 | — | 1.0 | 26.8 | — | -10% | -9% | -8% |
| ANIK | 0.3 | — | 2.1 | 496.5 | 0.2% | +5% | -4% | -5% |
| CGC | 0.3 | — | — | — | — | +7% | -55% | -26% |
| BIOA | 0.2 | — | — | — | — | +168% | — | -56% |
| SIGA | 0.2 | — | 2.0 | — | -9.1% | -70% | -21% | -30% |
| GLAS | 0.2 | — | 1.3 | — | -8.5% | -9% | -9% | -14% |
| ORGO | 0.1 | — | 0.2 | — | 16.3% | +7% | -8% | -27% |
| Median of these 10 | — | 1.5 | 261.7 | -6.6% | +7% | -9% | -26% |
; EV/Sales 0.2 vs. 1.5.
Growth vs. price
each dot a company · hover or tap for valuesAkebia Therapeutics, Inc. — questions
- What is Akebia Therapeutics, Inc.'s market cap?
- $157.1M.
- What is Akebia Therapeutics, Inc.'s price-to-sales ratio?
- 0.7.
Every figure on this page comes from Akebia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.